We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nine Types of GI Infections Rapidly and Simultaneously Detected

By LabMedica International staff writers
Posted on 06 Apr 2010
A gastrointestinal (GI) panel can detect and differentiate nine types of GI infections simultaneously so that physicians can quickly identify patients who have severe, life-threatening infections.

The nine bacterial pathogens targeted in the GI panel include Clostridium difficile; Clostridium difficile toxin B gene; Campylobacter jejuni; Escherichia coli strain 0157; Listeria monocytogenes; Salmonella enterica; Staphylococcus aureus; Vibrio cholerae; and Vibrio parahaemolyticus.

The panel uses Diatherix Laboratories' (Huntsville, AL, USA) technology--target enriched multiplex polymerase chain reaction (Tem-PCR). More...
Tem-PCR can identify multiple pathogens, detect coinfections, and determine genetic drug resistance in a single result.

"The GI infection C. difficile is becoming more of a hospital threat than [methicillin resistant Staphylococcus aureus] MRSA, and since hospitals are currently limited in their testing methods, this is the ideal time to introduce our new panel," said Dennis Grimaud, chairman and CEO of, Diatherix Laboratories Inc.

The GI panel is the sixth standard testing panel produced by Diatherix. Other panels include tests for infectious disease; Staphylococcus differentiation; respiratory infections; human papillomavirus typing; and respiratory viruses.

Diatherix Laboratories is an emerging leader in infectious disease diagnostics and drug resistance-detection services. Using a multiplexing platform, the company has developed a series of molecular differential diagnostic services that enable speed and accuracy for health care providers in the identification of disease-producing pathogens, leading to appropriate treatment for patients.

Related Links:

Diatherix Laboratories





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
BKE-B
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.